Comparing the current results to its competitors, Gsk Plc reported Revenue increase in the 4 quarter 2025 by 37.35 % year on year. The sales growth was above Gsk Plc's competitors' average revenue growth of 13.54 %, achieved in the same quarter.
Strong sales growth of 37.35 % in Overall company contributed to Gsk Plc increase in total revenue by 37.35 % Gsk Plc improved its market share in this segment, to approximately 22.4 %.
February 25, 2025
A New Legal Battle for GSK In a turn of events concerning GSK plc, the pharmaceutical heavyweight is finding itself under legal scrutiny as a class action lawsuit has emerged. Bronstein, Gewirtz and Grossman, LLC, a noted law firm recognized for its vigorous representation of shareholder interests, announced the lawsuit against GSK and certain of its officers. The filing, which has alerted investors who experienced substantial financial losses, underscores further complexities that the company now faces beyond its operational challenges.The legal action points to potential grievances by shareholders, spurred by significant losses. While detailed specifics of the lawsuit remain forthcoming, such legal proceed...
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Structure Therapeutics Inc is a biotechnology company that utilizes a structure-based approach to develop innovative therapeutics. They focus on identifying and targeting unique protein structures to create novel drugs for various diseases.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.
Sources:
Gsk Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gsk Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
